Please ensure Javascript is enabled for purposes of website accessibility

Why Sarepta Therapeutics Inc. Is Bouncing Back Today

By Brian Feroldi - Apr 22, 2016 at 4:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are bidding up shares after the FDA released its list of questions that will be used during next week's advisory committee meeting.


What: It's been a wild week for investors in Sarepta Therapeutics (SRPT 5.29%), a clinical-stage biotechnology company. Shares are up more than 36% as of 3:04 p.m. ET today on extremely heavy volume but they are still not even close to getting back to breakeven for the week after the drubbing it took yesterday.

SRPT Price Chart

So what: The company's stock is bouncing back today after traders got a look at the Food and Drug Administration's set of questions that will be used to guide next week's advisory committee meeting to discuss eteplirsen, Sarepta's drug for treating Duchenne muscular dystrophy that is currently pending regulatory approval. 

With the list of questions in hand, some traders appear to be more confident in the drug's chance of winning a recommendation from the committee than they were yesterday and are bidding up shares today as a result.

Now what: While it's still unknown which way the agency will vote on Monday, many believe that the briefing documents made available yesterday hint that the drug will not win a recommendation by the committee. If true, then it's extremely likely that the FDA will follow that recommendation and reject the company's application outright.

If that happens, then it will be a major blow to the Duchenne muscular dystrophy community and Sarepta Therapeutics alike as the company would most likely have to wait for its ongoing pivotal-stage trial to finish before it would refile eteplirsen for review. That outcome wouldn't sit well with investors or patients as the company's trial isn't scheduled to wrap up until 2019.

With the meeting scheduled to take place on Monday, you can bet that this company's stock will make a big move on based on which way the committee votes. Bulls and bears alike should plan accordingly.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sarepta Therapeutics, Inc. Stock Quote
Sarepta Therapeutics, Inc.
$74.65 (5.29%) $3.75

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.